ARTICLE | Deals
Lilly-Entos deal underscores importance of nucleic acid delivery tech
Partners to use Canadian biotech’s Fusogenix platform for non-viral nucleic acid delivery in neurology
January 6, 2022 10:59 PM UTC
The growing importance of nucleic acid delivery technologies is highlighted in Lilly’s latest deal, a neurology partnership with Entos.
The companies teamed up to use the Fusogenix proteo-lipid vehicle (PLV) delivery technology from Edmonton-based Entos Pharmaceuticals Inc. to deliver nucleic acid cargo from Eli Lilly and Co. Inc. (NYSE:LLY) to targets in the central and peripheral nervous systems; the specific nucleic acid modalities weren’t disclosed...